About this trial
There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female, aged 18 years and older
Provide signed and dated informed consent form.
Disqualifiers
None
Trial population
Chronically-infected with HBV, as defined by: Positive Hepatitis B surface antigen HBsAg) or HBV DNA result with a subsequent positive HBsAg or HBV DNA result at least 6 months after first positive result
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
prevalence of HDV
prevalence of HDV in patients with cirrhosis
prevalence of HDV
prevalence of HDV in patients with non cirrhosis
prevalence of HDV
prevalence of HDV in HIV positive people with injecting drug use
prevalence of HDV
prevalence of HDV in HIV negative people with injecting drug use
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
The HIV Netherlands Australia Thailand Research Collaboration
Lead sponsor
King Chulalongkorn Memorial Hospital
Collaborator
Thai Red Cross AIDS Research Centre
Collaborator
Siriraj Hospital
Collaborator
Taksin Hospital
Collaborator
Gilead Sciences
Collaborator